PSI selects goBalto's site ID cloud-based software to speed up trials

By Staff Reporter

- Last updated on GMT

PSI selects goBalto's site ID cloud-based software to speed up trials

Related tags: Clinical trial, Contract research organization

PSI has selected goBalto’s cloud-based Select module management system to help manage a multi-country Phase II clinical trial.

The Swiss contract research organisation (CRO) has chosen goBalto's end-to-end solution to assist with site identification, feasibility assessment and selection of sites for the study.

“Select simplifies the process of finding investigative sites by ensuring optimal fit and its integrated workflows allow our globally dispersed clinical research teams to collaborate in real-time,”​ Kirill Soldatov, director of process improvement at PSI, said in a statement.

“Investigative sites can then be quickly setup to enrol trial subjects using Activate.”

Activate is goBalto's clinical trial workflow software, already being used by PSI, and like Select is entirely cloud-based.

PSI is the latest CRO to select goBalto’s software. In December last year​, ICON opted for the Activate platform for all global studies spanning more than 50 countries in an effort to speed-up initiation of its clinical trials.

At the time, ICON VP Marie Keegan said: “Accelerating study startup timelines is a key component of our ICONIK Informatics Hub strategy which combines industry leading technologies with best practices to help our clients take time and cost from their development programs.

“Following a comprehensive review of our study startup activities, we adopted a range of new processes and procedures that have streamlined our site activation. We supplemented this with the capabilities of goBalto's Activate and Analyze to drive our study startup process, and are seeing significant positive impact on cycle time, quality and productivity as a result.”

More recently​, Australian CRO CMIC Holdings selected the Activate platform for multi-country studies being conducted in Malaysia, Singapore, Taiwan, Philippines, Thailand, Japan, and South Korea.

Related news

Show more

Related products

show more

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers